XLON
SCLP
Market cap129mUSD
Oct 07, Last price
9.40GBP
1D
-0.53%
1Q
-32.86%
Jan 2017
-34.90%
IPO
8.49%
Name
Scancell Holdings PLC
Chart & performance
P/E
—
P/S
20.71
EPS
—
Div yield, %
—
Shrs. gr., 5y
16.88%
Rev. gr., 5y
%
Revenues
5m
Net income
-12m
L+109.46%
CFO
-6m
L-61.01%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Scancell Holdings plc is a biopharmaceutical company in the clinical development stage, focused on creating novel vaccines and antibody-based treatments. Its mission is to tackle significant unmet medical needs in both cancer and infectious diseases. The firm's developing therapies include SCIB1, an ImmunoBody cancer vaccine specifically for metastatic melanoma; the SCIB2/iSCIB2 vaccine, currently being evaluated for its effectiveness against various solid tumors, such as non-small cell lung cancer; and Modi-1, which is progressing through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is working on Modi-2, designed to target homocitrullinated cancer antigens. The company also has SCOV1 and SCOV2 COVIDITY in its portfolio, which are DNA vaccines developed to fight the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
Key people
Non-Executive Chairman of the Board · since 2016
Clifford Michael Holloway
Chief Executive Officer · since 2018
Lindy Gillian Durrant
Chief Scientific Officer, Executive Director · since 2016
Richard Morley Goodfellow
Executive Director · since 2018
Sally Elizabeth Adams
Development Director, Director · since 2014
Martin Diggle
Non-Executive Director · since 2019
Non-Executive Director · since 2016
Headquarters & legal address
BELLHOUSE BUILDING
SANDERS ROAD
OXFORD SCIENCE PARK
OXFORD, OXF OX4 4GD
GB
SANDERS ROAD
OXFORD SCIENCE PARK
OXFORD, OXF OX4 4GD
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑04 | 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||